MiR-483-3p as a Prognostic Marker In Non-Small Cell Lung Cancer: Suppression of Tumor Progression via KIF3B...

MicroRNAs play wide roles in non-small cell lung cancer (NSCLC). To investigate the clinical value of miR-483-3p in NSCLC and its molecular target, 350 NSCLC patients were recruited in this study. RT-qPCR results showed that tumor histological expression of miR-483-3p progressively decreased as the tumor-node metastasis (TNM) stage increased. The receiver operating characteristic (ROC) curve displayed that histological miR-483-3p level can effectively distinguish NSCLC patients with high TNM stage (III) from those with low stage (I+II) (area under the ROC curve = 0.869). The Kaplan-Meier curve showed that NSCLC patients with low miR-483-3p expression demonstrated a lower 5-year overall survival rate. After adjusting for other confounding factors, multivariate Cox analysis further identified miR-483-3p as an independent protective factor for NSCLC survival. Mechanistically, RNA pull-down assay showed that upregulation of miR-483-3p was co-precipitated with KIF3B mRNA and inhibited its expression, thereby suppressing the malignant phenotypes of NSCLC cells and inducing apoptosis. In conclusion, downregulation of miR-483-3p serves as a poor prognostic marker in NSCLC, potentially affecting cancer progression by negatively regulating KIF3B.